AU1764900A - Novel streptococcus antigens - Google Patents
Novel streptococcus antigens Download PDFInfo
- Publication number
- AU1764900A AU1764900A AU17649/00A AU1764900A AU1764900A AU 1764900 A AU1764900 A AU 1764900A AU 17649/00 A AU17649/00 A AU 17649/00A AU 1764900 A AU1764900 A AU 1764900A AU 1764900 A AU1764900 A AU 1764900A
- Authority
- AU
- Australia
- Prior art keywords
- seq
- bvh
- fragments
- polypeptide
- analogs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000194017 Streptococcus Species 0.000 title description 32
- 108091007433 antigens Proteins 0.000 title description 25
- 102000036639 antigens Human genes 0.000 title description 25
- 239000000427 antigen Substances 0.000 title description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 246
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 245
- 229920001184 polypeptide Polymers 0.000 claims description 244
- 239000012634 fragment Substances 0.000 claims description 166
- 108091033319 polynucleotide Proteins 0.000 claims description 81
- 102000040430 polynucleotide Human genes 0.000 claims description 81
- 239000002157 polynucleotide Substances 0.000 claims description 81
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 29
- 239000013598 vector Substances 0.000 claims description 27
- 239000002773 nucleotide Substances 0.000 claims description 24
- 125000003729 nucleotide group Chemical group 0.000 claims description 24
- 208000015181 infectious disease Diseases 0.000 claims description 20
- 229960005486 vaccine Drugs 0.000 claims description 18
- 239000002671 adjuvant Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 206010035664 Pneumonia Diseases 0.000 claims description 7
- 230000027455 binding Effects 0.000 claims description 7
- 238000011321 prophylaxis Methods 0.000 claims description 7
- 208000031729 Bacteremia Diseases 0.000 claims description 5
- 201000009906 Meningitis Diseases 0.000 claims description 5
- 206010033078 Otitis media Diseases 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 241000282414 Homo sapiens Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims description 3
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000003248 secreting effect Effects 0.000 claims description 3
- 241000187654 Nocardia Species 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 230000000069 prophylactic effect Effects 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- 206010061372 Streptococcal infection Diseases 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 description 147
- 102000004169 proteins and genes Human genes 0.000 description 80
- 241000699670 Mus sp. Species 0.000 description 40
- 239000000047 product Substances 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 24
- 108700026244 Open Reading Frames Proteins 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 20
- 238000003752 polymerase chain reaction Methods 0.000 description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 description 18
- 241000588724 Escherichia coli Species 0.000 description 17
- 108020001507 fusion proteins Proteins 0.000 description 16
- 102000037865 fusion proteins Human genes 0.000 description 16
- 238000010367 cloning Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 230000004927 fusion Effects 0.000 description 13
- 230000003053 immunization Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 241001644525 Nastus productus Species 0.000 description 10
- 101100228799 Schizosaccharomyces pombe (strain 972 / ATCC 24843) gem6 gene Proteins 0.000 description 10
- 239000012472 biological sample Substances 0.000 description 10
- 239000003298 DNA probe Substances 0.000 description 8
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 238000011725 BALB/c mouse Methods 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 239000011543 agarose gel Substances 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 208000035109 Pneumococcal Infections Diseases 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 101100460200 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NEW1 gene Proteins 0.000 description 5
- 101100167780 Schizosaccharomyces pombe (strain 972 / ATCC 24843) coa2 gene Proteins 0.000 description 5
- 101100460198 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new14 gene Proteins 0.000 description 5
- 101100273916 Schizosaccharomyces pombe (strain 972 / ATCC 24843) wip1 gene Proteins 0.000 description 5
- 102000002933 Thioredoxin Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 101150066555 lacZ gene Proteins 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 108060008226 thioredoxin Proteins 0.000 description 5
- 229940094937 thioredoxin Drugs 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 101100172625 Schizosaccharomyces pombe (strain 972 / ATCC 24843) erh1 gene Proteins 0.000 description 4
- 101100460204 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new4 gene Proteins 0.000 description 4
- 101100322386 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new8 gene Proteins 0.000 description 4
- 101100460205 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new9 gene Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108020003215 DNA Probes Proteins 0.000 description 3
- 102000002265 Human Growth Hormone Human genes 0.000 description 3
- 108010000521 Human Growth Hormone Proteins 0.000 description 3
- 239000000854 Human Growth Hormone Substances 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 101100255212 Schizosaccharomyces pombe (strain 972 / ATCC 24843) rsa3 gene Proteins 0.000 description 3
- 101100210181 Schizosaccharomyces pombe (strain 972 / ATCC 24843) vts1 gene Proteins 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- 241000680505 Streptococcus pneumoniae WU2 Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000009920 chelation Effects 0.000 description 3
- 239000007330 chocolate agar Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 229940124733 pneumococcal vaccine Drugs 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 229940023143 protein vaccine Drugs 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101100390985 Schizosaccharomyces pombe (strain 972 / ATCC 24843) fmc1 gene Proteins 0.000 description 2
- 101100460203 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new2 gene Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000007479 molecular analysis Methods 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150000874 11 gene Proteins 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- 101150066375 35 gene Proteins 0.000 description 1
- 101710117373 92 kDa protein Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101100096227 Bacteroides fragilis (strain 638R) argF' gene Proteins 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100354186 Mycoplasma capricolum subsp. capricolum (strain California kid / ATCC 27343 / NCTC 10154) ptcA gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100460197 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new13 gene Proteins 0.000 description 1
- 101100460199 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new15 gene Proteins 0.000 description 1
- 101100221189 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new16 gene Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000647261 Stellaria umbellata Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003497 anti-pneumococcal effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 101150056313 argF gene Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 101150022503 phoR gene Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 229960001973 pneumococcal vaccines Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- -1 synthetic multimers) Polymers 0.000 description 1
- ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 101150057627 trxB gene Proteins 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2005209689A AU2005209689B2 (en) | 1998-12-23 | 2005-09-13 | Novel streptococcus antigens |
| AU2008229967A AU2008229967B2 (en) | 1998-12-23 | 2008-10-16 | Novel streptococcus antigens |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11380098P | 1998-12-23 | 1998-12-23 | |
| US60113800 | 1998-12-23 | ||
| PCT/CA1999/001218 WO2000039299A2 (en) | 1998-12-23 | 1999-12-20 | Streptococcus antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005209689A Division AU2005209689B2 (en) | 1998-12-23 | 2005-09-13 | Novel streptococcus antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1764900A true AU1764900A (en) | 2000-07-31 |
Family
ID=22351610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU17649/00A Abandoned AU1764900A (en) | 1998-12-23 | 1999-12-20 | Novel streptococcus antigens |
Country Status (29)
| Country | Link |
|---|---|
| EP (2) | EP1141306B1 (enExample) |
| JP (2) | JP4761623B2 (enExample) |
| KR (4) | KR100891398B1 (enExample) |
| CN (3) | CN101134775A (enExample) |
| AP (1) | AP2001002199A0 (enExample) |
| AR (1) | AR029322A1 (enExample) |
| AT (1) | ATE394489T1 (enExample) |
| AU (1) | AU1764900A (enExample) |
| BR (1) | BR9916477A (enExample) |
| CA (1) | CA2356836C (enExample) |
| CL (1) | CL2009002037A1 (enExample) |
| CY (3) | CY1108223T1 (enExample) |
| CZ (2) | CZ302790B6 (enExample) |
| DE (1) | DE69938670D1 (enExample) |
| DK (3) | DK1141306T3 (enExample) |
| EA (1) | EA007409B1 (enExample) |
| ES (3) | ES2306528T3 (enExample) |
| HU (1) | HU229664B1 (enExample) |
| IL (3) | IL143905A0 (enExample) |
| MX (1) | MXPA01006427A (enExample) |
| NO (1) | NO330800B1 (enExample) |
| NZ (1) | NZ512574A (enExample) |
| OA (1) | OA11736A (enExample) |
| PL (3) | PL205041B1 (enExample) |
| PT (3) | PT1141306E (enExample) |
| TR (2) | TR200200633T2 (enExample) |
| UY (1) | UY25877A1 (enExample) |
| WO (1) | WO2000039299A2 (enExample) |
| ZA (1) | ZA200105114B (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1757697A3 (en) | 1998-02-20 | 2007-05-30 | ID Biomedical Corporation | Group B streptococcus antigens |
| US20030134407A1 (en) | 1998-07-27 | 2003-07-17 | Le Page Richard William Falla | Nucleic acids and proteins from Streptococcus pneumoniae |
| EP1801218A3 (en) * | 1998-07-27 | 2007-10-10 | Sanofi Pasteur Limited | Nucleic acids and proteins from streptococcus pneumoniae |
| WO2000037105A2 (en) * | 1998-12-21 | 2000-06-29 | Medimmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| US7128918B1 (en) | 1998-12-23 | 2006-10-31 | Id Biomedical Corporation | Streptococcus antigens |
| DK1141306T3 (da) * | 1998-12-23 | 2008-08-18 | Id Biomedical Corp | Streptococcus-antigener |
| ATE412673T1 (de) | 2000-06-12 | 2008-11-15 | Univ Saskatchewan | Chimäres gapc protein aus streptococcus und dessen verwendung zur impfung und diagnostik |
| US6833134B2 (en) | 2000-06-12 | 2004-12-21 | University Of Saskacthewan | Immunization of dairy cattle with GapC protein against Streptococcus infection |
| US6866855B2 (en) | 2000-06-12 | 2005-03-15 | University Of Saskatchewan | Immunization of dairy cattle with GapC protein against Streptococcus infection |
| EP1303612A2 (en) * | 2000-06-20 | 2003-04-23 | Shire Biochem Inc. | Streptococcus antigens |
| US7074415B2 (en) | 2000-06-20 | 2006-07-11 | Id Biomedical Corporation | Streptococcus antigens |
| AU2002242549A1 (en) * | 2001-03-30 | 2002-10-15 | Shire Biochem Inc. | Streptococcus pyogenes antigens and corresponding dna fragments |
| JP4374245B2 (ja) * | 2001-07-06 | 2009-12-02 | アイディー バイオメディカル コーポレイション | グループｂ連鎖球菌の抗原及び対応するｄｎａ断片 |
| GB0130228D0 (en) * | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
| WO2003054007A2 (en) * | 2001-12-20 | 2003-07-03 | Shire Biochem Inc. | Streptococcus antigens |
| PT1601770E (pt) * | 2003-03-04 | 2009-12-07 | Intercell Ag | Antigénios de streptococcus pyogenes |
| AU2004230244B2 (en) | 2003-04-15 | 2011-09-22 | Intercell Ag | S. pneumoniae antigens |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| US20090010959A1 (en) | 2005-12-22 | 2009-01-08 | Ralph Leon Biemans | Pneumococcal Polysaccharide Conjugate Vaccine |
| HRP20151122T1 (hr) | 2007-06-26 | 2015-11-20 | Glaxosmithkline Biologicals S.A. | Cjepivo koje sadrži konjugate polisaharida iz kapsule bakterije streptococcus pneumoniae |
| WO2009012588A1 (en) * | 2007-07-23 | 2009-01-29 | Sanofi Pasteur Limited | Immunogenic polypeptides and monoclonal antibodies |
| CA2720961A1 (en) | 2008-04-16 | 2009-10-22 | William Ripley Ballou, Jr. | Streptococcus pneumonia vaccine |
| US8962026B2 (en) | 2008-09-26 | 2015-02-24 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
| EP2424562B1 (en) | 2009-04-30 | 2015-10-07 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
| WO2010132833A1 (en) | 2009-05-14 | 2010-11-18 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
| NZ620441A (en) | 2009-09-03 | 2015-08-28 | Pfizer Vaccines Llc | Pcsk9 vaccine |
| GB201003920D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
| JP6046632B2 (ja) | 2010-12-03 | 2016-12-21 | サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ | 肺炎球菌に対する免疫用組成物 |
| EP2665490B1 (en) * | 2011-01-20 | 2020-03-04 | Genocea Biosciences, Inc. | Vaccines and compositions against streptococcus pneumoniae |
| US20140004142A1 (en) | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
| EA201391456A1 (ru) | 2011-05-17 | 2014-05-30 | Глаксосмитклайн Байолоджикалс С.А. | ВАКЦИНА ПРОТИВ Streptococcus pneumoniae |
| US10161940B2 (en) * | 2012-01-05 | 2018-12-25 | Deutsches Krebsforschungszentrum | Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers |
| EP2931743A4 (en) * | 2012-12-14 | 2016-08-03 | Sanofi Pasteur Ltd | METHOD FOR ASSESSING IMMUNOGENICITY |
| PT3096785T (pt) | 2014-01-21 | 2020-10-13 | Pfizer | Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas |
| US20160324949A1 (en) | 2014-01-21 | 2016-11-10 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
| SI3096783T1 (sl) | 2014-01-21 | 2021-09-30 | Pfizer Inc. | Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP3104886B1 (en) | 2014-02-14 | 2018-10-17 | Pfizer Inc | Immunogenic glycoprotein conjugates |
| MX395525B (es) | 2015-01-15 | 2025-03-25 | Pfizer | Composiciones inmunogenicas para usar en vacunas neumococicas. |
| AU2016295566B2 (en) | 2015-07-21 | 2019-06-20 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| EP3377098A1 (en) | 2015-11-20 | 2018-09-26 | Pfizer Inc | Immunogenic compositions for use in pneumococcal vaccines |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| US11413344B2 (en) | 2017-01-20 | 2022-08-16 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US20220016229A1 (en) | 2018-12-12 | 2022-01-20 | Pfizer Inc. | Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| CA3136278A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| CA3148824A1 (en) | 2019-07-31 | 2021-02-04 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
| KR20220092572A (ko) | 2019-11-01 | 2022-07-01 | 화이자 인코포레이티드 | 에스케리키아 콜라이 조성물 및 그 방법 |
| KR20220144393A (ko) | 2020-02-21 | 2022-10-26 | 화이자 인코포레이티드 | 당류의 정제 |
| MX2022010350A (es) | 2020-02-23 | 2022-09-19 | Pfizer | Composiciones de esquerichia coli y sus metodos. |
| US20230383324A1 (en) | 2020-10-22 | 2023-11-30 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| AU2021368151B2 (en) | 2020-10-27 | 2024-09-05 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| WO2022097010A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| CA3218544A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| US20220387576A1 (en) | 2021-05-28 | 2022-12-08 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP4346892A2 (en) | 2021-05-28 | 2024-04-10 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| JP2025508749A (ja) | 2022-01-13 | 2025-04-10 | ファイザー・インク | コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用 |
| WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
| US20250312433A1 (en) | 2022-05-11 | 2025-10-09 | Pfizer Inc. | Process for Producing of Vaccine Formulations With Preservatives |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| IL321062A (en) | 2022-11-22 | 2025-07-01 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP4626405A1 (en) | 2022-12-01 | 2025-10-08 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
| WO2024166008A1 (en) | 2023-02-10 | 2024-08-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024201324A2 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| KR20250169621A (ko) | 2023-04-14 | 2025-12-03 | 화이자 인코포레이티드 | 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN121263203A (zh) | 2023-05-19 | 2026-01-02 | 葛兰素史克生物有限公司 | 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法 |
| WO2025057078A1 (en) | 2023-09-14 | 2025-03-20 | Pfizer Inc. | Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof |
| WO2025133971A1 (en) | 2023-12-23 | 2025-06-26 | Pfizer Inc. | Improved methods for producing bacterial capsular saccharide glycoconjugates |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
| WO2025219904A1 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Improved methods for producing glycoconjugates by reductive amination in aprotic solvent |
| WO2025219908A2 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Media and fermentation methods for polysaccharide production in bacterial cell culture |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4431739A (en) | 1979-11-05 | 1984-02-14 | Genentech, Inc. | Transformant bacterial culture capable of expressing heterologous protein |
| US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
| US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| EP0656014B1 (en) * | 1993-03-19 | 2003-05-14 | LINDAHL, Gunnar | Protein rib, a cell surface protein that confers immunity to many strains of the group b streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition |
| EP0832238A1 (en) * | 1995-06-07 | 1998-04-01 | Biochem Vaccines Inc. | Streptococcal heat shock proteins members of the hsp70 family |
| US5928895A (en) * | 1996-09-24 | 1999-07-27 | Smithkline Beecham Corporation | IgA Fc binding protein |
| US5882896A (en) * | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | M protein |
| DK0942983T4 (en) * | 1996-10-31 | 2014-12-01 | Human Genome Sciences Inc | Streptococcus pneumoniae antigens and vaccines |
| CN1291233A (zh) * | 1997-09-24 | 2001-04-11 | 美国明尼苏达州大学 | 来自肺炎链球菌之人类补体c3降解蛋白酶 |
| CA2328399A1 (en) * | 1998-04-23 | 1999-10-28 | University Of Alabama At Birmingham | Pneumococcal surface protein c(pspc), epitopic regions and strain selection thereof, and uses therefor |
| JP2002531055A (ja) * | 1998-07-27 | 2002-09-24 | マイクロビアル テクニクス リミティッド | 肺炎連鎖球菌のタンパク質及び核酸分子 |
| JP2002521058A (ja) * | 1998-07-27 | 2002-07-16 | マイクロビアル テクニクス リミティッド | 肺炎連鎖球菌由来の核酸及びタンパク質 |
| CN1352691A (zh) * | 1998-09-24 | 2002-06-05 | 美国明尼苏达州大学 | 来自肺炎链球菌的人补体c3降解性多肽 |
| WO2000037105A2 (en) * | 1998-12-21 | 2000-06-29 | Medimmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| DK1141306T3 (da) * | 1998-12-23 | 2008-08-18 | Id Biomedical Corp | Streptococcus-antigener |
-
1999
- 1999-12-20 DK DK99960748T patent/DK1141306T3/da active
- 1999-12-20 KR KR1020067025282A patent/KR100891398B1/ko not_active Expired - Fee Related
- 1999-12-20 PL PL382437A patent/PL205041B1/pl unknown
- 1999-12-20 OA OA1200100165A patent/OA11736A/en unknown
- 1999-12-20 EA EA200100565A patent/EA007409B1/ru not_active IP Right Cessation
- 1999-12-20 JP JP2000591190A patent/JP4761623B2/ja not_active Expired - Fee Related
- 1999-12-20 PL PL349777A patent/PL206576B1/pl unknown
- 1999-12-20 HU HU0104774A patent/HU229664B1/hu not_active IP Right Cessation
- 1999-12-20 KR KR1020107009285A patent/KR101078919B1/ko not_active Expired - Fee Related
- 1999-12-20 AT AT99960748T patent/ATE394489T1/de active
- 1999-12-20 DE DE69938670T patent/DE69938670D1/de not_active Expired - Lifetime
- 1999-12-20 MX MXPA01006427A patent/MXPA01006427A/es not_active IP Right Cessation
- 1999-12-20 CA CA2356836A patent/CA2356836C/en not_active Expired - Fee Related
- 1999-12-20 ES ES99960748T patent/ES2306528T3/es not_active Expired - Lifetime
- 1999-12-20 DK DK08155317.4T patent/DK1950302T3/da active
- 1999-12-20 NZ NZ512574A patent/NZ512574A/xx not_active IP Right Cessation
- 1999-12-20 CN CNA2007101481600A patent/CN101134775A/zh active Pending
- 1999-12-20 CN CNB998149047A patent/CN1191362C/zh not_active Expired - Fee Related
- 1999-12-20 TR TR2002/00633T patent/TR200200633T2/xx unknown
- 1999-12-20 PT PT99960748T patent/PT1141306E/pt unknown
- 1999-12-20 PT PT101803724T patent/PT2261358E/pt unknown
- 1999-12-20 CN CNB2005100037492A patent/CN100398653C/zh not_active Expired - Fee Related
- 1999-12-20 EP EP99960748A patent/EP1141306B1/en not_active Expired - Lifetime
- 1999-12-20 AU AU17649/00A patent/AU1764900A/en not_active Abandoned
- 1999-12-20 ES ES10180372.4T patent/ES2480417T3/es not_active Expired - Lifetime
- 1999-12-20 DK DK10180372.4T patent/DK2261358T3/da active
- 1999-12-20 AP APAP/P/2001/002199A patent/AP2001002199A0/en unknown
- 1999-12-20 PT PT81553174T patent/PT1950302E/pt unknown
- 1999-12-20 WO PCT/CA1999/001218 patent/WO2000039299A2/en not_active Ceased
- 1999-12-20 KR KR1020087008264A patent/KR101170203B1/ko not_active Expired - Fee Related
- 1999-12-20 CZ CZ20100674A patent/CZ302790B6/cs not_active IP Right Cessation
- 1999-12-20 CZ CZ20012161A patent/CZ303675B6/cs not_active IP Right Cessation
- 1999-12-20 ES ES08155317T patent/ES2400280T3/es not_active Expired - Lifetime
- 1999-12-20 BR BR9916477-9A patent/BR9916477A/pt active Search and Examination
- 1999-12-20 TR TR2001/02497T patent/TR200102497T2/xx unknown
- 1999-12-20 PL PL382438A patent/PL204073B1/pl not_active IP Right Cessation
- 1999-12-20 IL IL14390599A patent/IL143905A0/xx unknown
- 1999-12-20 KR KR1020017007963A patent/KR100802198B1/ko not_active Expired - Fee Related
- 1999-12-20 EP EP10180372.4A patent/EP2261358B1/en not_active Expired - Lifetime
- 1999-12-23 UY UY25877A patent/UY25877A1/es unknown
- 1999-12-23 AR ARP990106746A patent/AR029322A1/es not_active Application Discontinuation
-
2001
- 2001-06-19 NO NO20013045A patent/NO330800B1/no not_active IP Right Cessation
- 2001-06-21 IL IL143905A patent/IL143905A/en not_active IP Right Cessation
- 2001-06-21 ZA ZA200105114A patent/ZA200105114B/en unknown
-
2008
- 2008-07-29 CY CY20081100787T patent/CY1108223T1/el unknown
- 2008-09-21 IL IL194230A patent/IL194230A/en not_active IP Right Cessation
-
2009
- 2009-11-05 CL CL2009002037A patent/CL2009002037A1/es unknown
-
2010
- 2010-02-09 JP JP2010026521A patent/JP5039802B2/ja not_active Expired - Fee Related
-
2012
- 2012-12-27 CY CY20121101268T patent/CY1114722T1/el unknown
-
2014
- 2014-07-16 CY CY20141100536T patent/CY1115340T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2356836C (en) | Novel streptococcus antigens | |
| US8211437B2 (en) | Streptococcus antigens | |
| US7262024B2 (en) | Streptococcus antigens | |
| US20030228323A1 (en) | Novel group B streptococcus antigens | |
| US7074415B2 (en) | Streptococcus antigens | |
| AU2008229967B2 (en) | Novel streptococcus antigens | |
| EP1950302B1 (en) | Streptococcus antigens | |
| HK1118575B (en) | Streptococcus antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND APPLICANT'S NAME TO READ: SHIRE BIOCHEM INC. |